

Brussels, 28 November 2025 (OR. en)

15124/25

SAN 719 PHARM 159

NOTE

From:	Presidency
To:	Delegations
Subject:	AOB for the meeting of EPSCO (Health) of 2 December 2025:
	Presidency conferences
	- Information from the Presidency

In a time marked by global uncertainty and complex health challenges, the Danish Presidency focused on life science and preparedness, aiming to strengthen security of supply and innovation in the EU, promote access to medicines across Member States and boost the resilience of healthcare systems against manmade crises and natural disasters.

Information follows below on the high-level presidency conferences during the Danish presidency of EPSCO (health).

High-Level Conference 'How to Create More Resilient Health Care Systems in Europe?', Copenhagen, 15 September 2025

In conjunction with the informal EPSCO ministers' meeting in Copenhagen, the Presidency and Danish Industry hosted EU ministers and stakeholders representing patients, hospitals and industry, for a roundtable and panel debate on two main topics: 'How to Create More Resilient Health Care Systems in Europe?' and 'How can improved public-private collaboration help alleviate the demographic challenge in Europe?"

15124/25

EN

LIFE.5

The discussions highlighted first and foremost that there is no silver bullet or single cure for the challenges the EU is facing. The key deliverables, however, are well known: to secure the availability of critical medicines, to advance resilience and innovation, and to be more robust in withstanding threats such as antimicrobial resistance.

A strong life science sector makes EU health systems stronger. Strong, data-driven health systems should make Europe the obvious home for life science and clinical trials. Patients in Europe must have access to essential medicines – both innovative treatments and generics.

Arranged by Danish Industry

High-Level Conference 'Nordic Rare Disease Summit 2025', Copenhagen, 16-17 September 2025

Following the informal meeting of EPSCO minsters, the Danish Presidency co-hosted the 2025 Nordic Rare Disease Summit, which brought together leading experts, healthcare professionals, patients, decision makers and industry to discuss improved quality of life for people living with rare diseases through patient empowerment.

Building on the foundation of the previous Nordic Rare Disease Summits, the 2025 summit united stakeholders in a shared ambition to enhance quality of life, care, treatment and outcomes for individuals living with rare diseases across the Nordics and throughout the EU. By fostering collaboration between policymakers, industry leaders, researchers and healthcare providers, the summit served as a strategic platform to advance the life sciences competitiveness agenda.

Arranged by (patient partners) Sjældne Diagnoser, SBONN, (industry partners) Alexion Pharma Nordics AB, Novo Nordisk Health Care AG, Swedish Orphan Biovitrum AB, Takeda Pharma A/S.

15124/25 2 LIFE.5 EN

www.parlament.gv.at

Copenhagen Life Science Summit, Copenhagen, 9 October 2025

The Copenhagen Life Science Summit gathered leading European stakeholders across politics, industry, research and patient organisations. Many perspectives were presented at the conference, but one shared vision was that Europe has a global window of opportunity to strengthen its role in life sciences and health innovation – an opportunity that must be seized now. The European Competitiveness Compass sets the direction towards that goal, while Choose Europe for Life Sciences is the vehicle to position the EU as the world's most attractive destination for life sciences by 2030.

The life sciences have long been a driver for innovation, growth and healthcare resilience in Denmark. By inviting key stakeholders from EU institutions, member states, patient organisations, universities and industry to meet together, the aim was to support Europe's efforts in shaping a common path for future growth, resilience and patient impact.

High-Level Conclusions were published highlighting the key takeaways and to provide input for policy development, partner engagement and the next European stepping stones for life sciences, health innovation and global competitiveness.

Arranged by Rigshospitalet, The Capital Region of Denmark and Healthcare Denmark.

High-Level Conference on AMR, Aarhus and Copenhagen, 19-20 November 2025

The High-Level Conference on AMR was a two-day conference focusing on the patient's perspective on antibiotic resistance, and on how to best protect patients and European healthcare systems from the threat of resistance through more strategic prevention, such as vaccines, improved use of diagnostics and strengthened frameworks for the development of new and innovative medicines.

AMR places a heavy burden on healthcare systems, straining their capacity and budgets. Ultimately it can undermine European citizens' trust in healthcare systems. Tackling AMR requires coordinated political action in the EU and continued follow-up on the coordinated measures from the June 2023 Council Recommendation.

15124/25 LIFE.5

FN

The conference developed an AMR position paper to add evidence, ideas and momentum to the European efforts to step up action to prevent, prepare and protect against infections and AMR in hospitals.

Arranged by The Danish AMR Alliance, Aarhus University Hospital and the European University Hospital Alliance.

15124/25 LIFE.5